{"preliminary_commentary":{"by_channel":{"x_thread":3},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":false},"commentary_summary":null,"drugs_tested":[["KITE-363"],["KITE-753"]],"indication":"relapsed and/or refractory B-cell lymphoma","name":"PALISADES-1","nct_id":"NCT04989803","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=palisades-1-nct04989803. The price is an estimate of verified statements from the commentary indexed so far. Final coverage is set when the report is built. You never pay more than quoted: if the report is delivered at a smaller size, you pay that size's price, and anything paid above it is refunded. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_rule":"Never more than quoted: the buyer pays the smaller of price_usd and the price the delivered edition is sold at.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":"PALISADES-1","arms":[{"description":"Phase 1a (Dose escalation): Participants with r/r large B-cell lymphoma will receive lymphodepleting chemotherapy with cyclophosphamide and fludarabine followed by a single target starting dose of KITE-363 chimeric antigen receptor (CAR) transduced autologous T cells. Based on dose limiting toxicities (DLTs) observed in the first cohort, additional participants will be enrolled and administered escalating dose of KITE-363.\n\nPhase 1b (Dose expansion): After completion of dose escalation, additional participants with r/r B-cell lymphoma across different disease indications will receive lymphodepleting chemotherapy with cyclophosphamide and fludarabine followed by a single dose of KITE-363 at 1 or more dose-level deemed to be tolerable.\n\n\\[Recruitment completed for this arm\\]","label":"Phase 1 a/b: KITE-363","type":"EXPERIMENTAL"},{"description":"Phase 1a (Dose escalation): Participants with r/r large B-cell lymphoma will receive lymphodepleting chemotherapy with cyclophosphamide and fludarabine followed by a single target starting dose of KITE-753 chimeric antigen receptor (CAR) transduced autologous T cells. Based on dose limiting toxicities (DLTs) observed in the first cohort, additional participants will be enrolled and administered escalating dose of KITE-753.\n\nPhase 1b (Dose expansion): After completion of dose escalation, additional participants with r/r B-cell lymphoma across different disease indications will receive lymphodepleting chemotherapy with cyclophosphamide and fludarabine followed by a single dose of KITE-753 at 1 or more dose-level deemed to be tolerable.\n\n\\[Recruitment open for frontline LBCL and r/r MCL for this arm\\]","label":"Phase 1 a/b: KITE-753","type":"EXPERIMENTAL"},{"description":"Participants with r/r large B-cell lymphoma who have received at least 2 prior lines of systemic therapy will receive lymphodepleting chemotherapy with cyclophosphamide and fludarabine followed by a single target starting dose of KITE-753 chimeric antigen receptor (CAR) transduced autologous T cells /kg intravenously (IV).","label":"Phase 2: KITE-753","type":"EXPERIMENTAL"}],"collaborators":[],"completion_date":{"date":"2030-02","type":"ESTIMATED"},"conditions":["Relapsed and/or Refractory B-cell Lymphoma"],"enrollment":{"count":247,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"Cyclophosphamide","otherNames":[],"type":"DRUG"},{"name":"Fludarabine","otherNames":[],"type":"DRUG"},{"name":"KITE-363","otherNames":[],"type":"BIOLOGICAL"},{"name":"KITE-753","otherNames":[],"type":"BIOLOGICAL"}],"last_update":"2026-10-28","lead_sponsor":"Kite, A Gilead Company","official_title":"A Phase 1/2 Open-label, Multicenter Study Evaluating the Safety and Efficacy of KITE-363 or KITE-753, Autologous Anti-CD19/CD20 CAR T-cell Therapies, in Subjects With Relapsed and/or Refractory B-cell Lymphoma","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE1","PHASE2"],"primary_completion_date":{"date":"2030-02","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Phase 1a: Percentage of Participants Experiencing Adverse Events Defined as Dose-limiting Toxicities (DLTs) After the Infusion of KITE-363 or KITE-753","timeFrame":"Up to 28 days"},{"measure":"Phase 1b: Objective Response Rate (ORR) for KITE-363 and KITE-753 as per investigator's assessment.","timeFrame":"Up to 24 months"},{"measure":"Phase 2: ORR as per central assessment for KITE-753","timeFrame":"Up to 36 months"}],"references":[],"start_date":{"date":"2021-10-27","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Study of KITE-363 or KITE-753 in Participants With Relapsed and/or Refractory B-cell Lymphoma","url":"https://clinicaltrials.gov/study/NCT04989803"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.2","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/palisades-1-nct04989803"}